Home    Back

Sunphenon egcg    (DrugBank: EGCG)

3 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica4
17Multiple system atrophy1
113Muscular dystrophy1

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 3,050 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00799890
(ClinicalTrials.gov)		May 200928/11/2008Sunphenon in Progressive Forms of Multiple SclerosisMonocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple SclerosisMultiple SclerosisDrug: Sunphenon EGCG;Drug: PlaceboFriedemann PaulTAIYO EUROPECompleted18 Years65 YearsAll61Phase 2;Phase 3Germany
2NCT00525668
(ClinicalTrials.gov)		September 20074/9/2007Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)Relapsing-remitting Multiple SclerosisDrug: epigallocatechin-gallate (Sunphenon);Drug: placeboCharite University, Berlin, GermanyNULLCompleted18 Years60 YearsAll120Phase 1;Phase 2Germany
3EUCTR2006-006323-39-DE
(EUCTR)		19/06/200705/03/2007Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MSSunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS relapsing-remitting multiple sclerosisICD classification: G35.1Product Name: Sunphenon
Other descriptive name: Sunphenon EGCg TM		Charité-Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes		100Germany
4EUCTR2008-005213-22-DE
(EUCTR)		22/08/2008SUPREMES - Sunphenon in progressive forms of multiple sclerosisSUPREMES - Sunphenon in progressive forms of multiple sclerosis - SUPREMES primary and secondary progressive forms of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Sunphenon
Other descriptive name: Sunphenon EGCg		Charite Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes		60Phase 2;Phase 3Germany

17. Multiple system atrophy    [ 107 clinical trials,   153 drugs,   (DrugBank: 48 drugs),   59 drug target genes,   104 drug target pathways]
Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 107 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2012-000928-18-DE
(EUCTR)		21/11/201328/06/2013Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA)Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) - Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach Progression of patients with Multiple System Atrophy (MSA);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Sunphenon EGCg
INN or Proposed INN: EGCG
Other descriptive name: GREEN TEA LEAF		Hospital of the Ludwig-Maximilians-University of MunichNULLNot RecruitingFemale: yes
Male: yes		86Phase 3Germany

113. Muscular dystrophy    [ 567 clinical trials,   442 drugs,   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways]
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 567 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2009-016482-28-DE
(EUCTR)		25/06/201015/03/2010SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular DystrophySUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy - SUNIMUD Duchenne Muscular Dystrophy;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]Product Name: Sunphenon EGCG
INN or Proposed INN: Sunphenon 		Charite Universitätsmedizin BerlinNULLNot RecruitingFemale: no
Male: yes		40Phase 2Germany

Back to top